ライフサイエンスコーパス: ferumoxytol

1 inistration-approved iron oxide nanoparticle ferumoxytol.

2 nically approved magnetic nanoparticle (MNP) ferumoxytol.

3 6) 2Bck/J mice received rhodamine-conjugated ferumoxytol.

4 eefold increase in T2 relaxivity compared to ferumoxytol.

5 adodiamide and 72 hours after treatment with ferumoxytol.

6 ged with magnetic resonance (MR) imaging and ferumoxytol.

7 athymic rats were injected with intravenous ferumoxytol (0.5 mmol iron per kilogram of body weight)

8 on gluconate, 2.0 (95% CI 1.2, 3.5); and for ferumoxytol, 2.2 (95% CI, 1.1-4.3).

9 wley rats (6-8 weeks old) were injected with ferumoxytol 48 hours prior to extraction of MSCs from bo

10 ext day, nine rats underwent MR imaging with ferumoxytol (60 muL).

11 ducts combined (iron sucrose, gluconate, and ferumoxytol) (95% CI, 20.0-29.5 per 100,000) , with an a

12 l experience with renal transplant MRA using ferumoxytol (a nonnephrotoxic medication) as a contrast

13 egimen of two doses of 510 mg of intravenous ferumoxytol administered rapidly within 5 +/- 3 d was we

14 hemoglobin increased 0.62 +/- 1.02 g/dl with ferumoxytol and 0.13 +/- 0.93 g/dl with oral iron.

15 icacy end point, was 0.82 +/- 1.24 g/dl with ferumoxytol and 0.16 +/- 1.02 g/dl with oral iron (P < 0

16 hemoglobin increased 1.16 +/- 1.49 g/dl with ferumoxytol and 0.19 +/- 1.14 g/dl with oral iron.

17 d in 10.6% of patients who were treated with ferumoxytol and 24.0% of those who were treated with ora

18 nal control animal each received intravenous ferumoxytol and bilateral scaffold-only implants (withou

19 ltured MSCs regain the capability to take up Ferumoxytol and exhibit an intracellular iron concentrat

20 Five patients with mismatched high rCBV with ferumoxytol and low rCBV with gadoteridol had an mOS of

21 itro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 a

22 dministration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been

23 awley rats received intravenous injection of ferumoxytol, and 18 Jax C57BL/6-Tg (Csf1r-EGFP-NGFR/FKBP

24 Ferumoxytol as a blood pool agent facilitates differenti

25 s of IV iron dextran, gluconate, sucrose, or ferumoxytol as reported in outpatient Medicare claims da

26 We demonstrate that (89)Zr-ferumoxytol can be used for high-resolution tomographic

27 Intravenous ferumoxytol can be used to effectively label MSCs in viv

28 linically approved iron oxide nanoparticles (Ferumoxytol) can be utilized to carry one or multiple dr

29 ce microscopy (IVM), where nearly 90% of all ferumoxytol-containing cells were found to be macrophage

30 Our results suggest that ferumoxytol could be applied 'off label' to protect the

31 In 1 of 16 subjects, MRA with ferumoxytol demonstrated complete arterial occlusion of

32 Macrophages exposed to ferumoxytol displayed increased mRNA associated with pro

33 sion Endogenous labeling of macrophages with ferumoxytol enables noninvasive detection of innate immu

34 sess the technical feasibility of the use of ferumoxytol-enhanced (FE) magnetic resonance (MR) angiog

35 Compared with precontrast TOF images, ferumoxytol-enhanced bright-blood images had higher cont

36 wo-dimensional time-of-flight (TOF) imaging, ferumoxytol-enhanced bright-blood imaging, and ferumoxyt

37 tween thrombus and blood (P = .051), whereas ferumoxytol-enhanced dark-blood images showed significan

38 rumoxytol-enhanced bright-blood imaging, and ferumoxytol-enhanced dark-blood imaging, were applied.

39 Image quality for precontrast and ferumoxytol-enhanced images was analyzed by using a four

40 Image quality of ferumoxytol-enhanced images was uniformly superior to th

41 Ferumoxytol-enhanced magnetic resonance (MR) imaging of

42 CNR efficiency were compared between TOF and ferumoxytol-enhanced MR angiography by using a Wilcoxon-

43 Ferumoxytol-enhanced MR angiography had significantly be

44 study demonstrates the feasibility of using ferumoxytol-enhanced MR angiography in imaging hemodialy

45 TOF and first-pass ferumoxytol-enhanced MR angiography were performed in 10

46 artifacts were greatly reduced by the use of ferumoxytol-enhanced MR angiography.

47 Ferumoxytol-enhanced MR imaging can depict DVT with a du

48 ere retrospectively identified who underwent ferumoxytol-enhanced MRA after a nondiagnostic ultrasoun

49 Our study suggests that ferumoxytol-enhanced MRA may be a novel, safe method to

50 weighted MRI scans for tumour detection with ferumoxytol-enhanced T1-weighted MRI scans for anatomica

51 Ferumoxytol-enhanced whole-body diffusion-weighted MRI c

52 enerated by coregistration of colour-encoded ferumoxytol-enhanced whole-body diffusion-weighted MRI s

53 (GFP), which enables in vivo correlation of ferumoxytol enhancement at MR imaging with macrophage qu

54 hed stem cell implants demonstrated stronger ferumoxytol enhancement than did matched stem cell impla

55 abeled in vivo with intravenous injection of ferumoxytol (Feraheme; AMAG Pharmaceuticals, Lexington,

56 we present a multimodal nanoparticle, (89)Zr-ferumoxytol, for the enhanced detection of LNs with PET/

57 In North America, the iron supplement ferumoxytol has gained considerable interest as an MR co

58 nd Drug Administration (FDA)-approved drugs--ferumoxytol, heparin and protamine--in serum-free medium

59 We observed that the ferumoxytol-heparin-protamine (HPF) nanocomplexes were s

60 pg/MSC, comparable to that obtained by using Ferumoxytol-heparin-protamine nanocomplex; and (ii) cell

61 Immediately after ferumoxytol imaging, six rats received bevacizumab (45 m

62 om perfusion MR imaging with gadoteridol and ferumoxytol in 19 patients with apparently progressive G

63 loendothelial system by means of intravenous ferumoxytol injection can be utilized to monitor differe

64 hout cells) or bilateral MASIs without prior ferumoxytol injection.

65 Ferumoxytol is a novel intravenous iron product that can

66 Conclusion The protein corona around ferumoxytol nanoparticles can facilitate stem cell label

67 if the formation of a protein corona around ferumoxytol nanoparticles can facilitate stem cell label

68 , we show an intrinsic therapeutic effect of ferumoxytol on the growth of early mammary cancers, and

69 d recruitment of enhanced GFP- and rhodamine-ferumoxytol-positive macrophages into stem cell transpla

70 Conversely, ferumoxytol provides consistent assessment of tumor rCBV

71 With ferumoxytol, rCBV was low in nine (47%) patients, with m

72 In vivo, ferumoxytol significantly inhibited growth of subcutaneo

73 ith an iron oxide blood pool contrast agent, ferumoxytol, to depict deep venous thrombosis (DVT).

74 In addition, intravenous ferumoxytol treatment before intravenous tumour cell cha

75 Ferumoxytol uptake by these MSCs was evaluated with fluo

76 beled MSCs demonstrated significantly higher ferumoxytol uptake compared with ex vivo-labeled cells.

77 ffusion-weighted MRI and the iron supplement ferumoxytol, used off-label as a contrast agent.

78 Ferumoxytol was administered as a bolus solution contain

79 whereas the magnitude of rCBV decrease with ferumoxytol was constant regardless of whether contrast

80 Materials and Methods Ferumoxytol was incubated in media containing human seru

81 Conversely, rCBVs obtained with ferumoxytol were high (>1.75) and remained constant with

82 Analyses involving ferumoxytol were limited to the period January 2010 to D

83 No adverse events after administration of ferumoxytol were recorded.

84 nd expanded MSCs can be ex-vivo labeled with Ferumoxytol, which is currently the only FDA approved SP

85 3:1 ratio to two 510-mg doses of intravenous ferumoxytol within 5 +/- 3 d or 200 mg of elemental oral

86 useful for expanding MSCs and labeling with Ferumoxytol, without the need for transfection agents an